# A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

> **NCT00445094** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 120 (actual)

## Conditions studied

- Infection
- Pneumonia

## Interventions

- **DRUG:** MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days
- **DRUG:** Comparator: amikacin / Duration of Treatment: 3 Days
- **DRUG:** Comparator: tazocin / Duration of Treatment: 3 Days
- **DRUG:** Comparator: vancomycin / Duration of Treatment: 3 Days

## Key facts

- **NCT ID:** NCT00445094
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445094, "A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00445094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*